In glioma clinical trials, a TKI BLZ945 showed promising results when combined with insulin-like growth factor 1 receptor (IGF1R) and phosphoinositol 3 kinase (PI3K) inhibitors69. Here, IGF1R is linked to central nervous system cancer.